全文获取类型
收费全文 | 1273篇 |
免费 | 119篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 60篇 |
妇产科学 | 40篇 |
基础医学 | 126篇 |
口腔科学 | 30篇 |
临床医学 | 198篇 |
内科学 | 261篇 |
皮肤病学 | 14篇 |
神经病学 | 43篇 |
特种医学 | 277篇 |
外科学 | 124篇 |
综合类 | 27篇 |
一般理论 | 3篇 |
预防医学 | 57篇 |
眼科学 | 7篇 |
药学 | 82篇 |
中国医学 | 5篇 |
肿瘤学 | 41篇 |
出版年
2023年 | 9篇 |
2021年 | 13篇 |
2020年 | 12篇 |
2019年 | 8篇 |
2018年 | 25篇 |
2017年 | 13篇 |
2016年 | 23篇 |
2015年 | 23篇 |
2014年 | 32篇 |
2013年 | 35篇 |
2012年 | 23篇 |
2011年 | 28篇 |
2010年 | 44篇 |
2009年 | 62篇 |
2008年 | 39篇 |
2007年 | 27篇 |
2006年 | 31篇 |
2005年 | 22篇 |
2004年 | 20篇 |
2003年 | 29篇 |
2002年 | 22篇 |
2001年 | 26篇 |
2000年 | 20篇 |
1999年 | 25篇 |
1998年 | 57篇 |
1997年 | 59篇 |
1996年 | 67篇 |
1995年 | 50篇 |
1994年 | 46篇 |
1993年 | 49篇 |
1992年 | 27篇 |
1991年 | 18篇 |
1990年 | 30篇 |
1989年 | 44篇 |
1988年 | 39篇 |
1987年 | 42篇 |
1986年 | 39篇 |
1985年 | 32篇 |
1984年 | 22篇 |
1983年 | 12篇 |
1982年 | 26篇 |
1981年 | 19篇 |
1980年 | 14篇 |
1979年 | 10篇 |
1978年 | 7篇 |
1977年 | 15篇 |
1976年 | 15篇 |
1975年 | 16篇 |
1966年 | 3篇 |
1928年 | 6篇 |
排序方式: 共有1399条查询结果,搜索用时 265 毫秒
1.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
2.
OBJECTIVES: To determine whether the increase in the incidence of injury found for the first summer season in which rugby league (RL) was played in the UK was repeated in subsequent summer seasons. DESIGN: A retrospective and prospective cohort study design. SETTING AND PARTICIPANTS: Injuries were recorded from all players who took part in 141 games over 3 summer seasons (1997 to 1999) for 1 professional team. These were compared against rates from previously collected data for 3 earlier winter and 1 summer season. ASSESSMENT OF RISK FACTORS: For each injury it was recorded in which season it occurred; how many games or training sessions, if any, were subsequently missed; the type, site and severity of injury. MAIN OUTCOME MEASURES: Injuries were reported as rate per 1000 hours, also broken down into severity according to the number of games missed and whether subsequent training sessions were missed. RESULTS: A sustained increase in injury incidence has been found comparing summer RL over RL played in the winter. There was an increase in injury rates for all sites and types, but not all reached significance. CONCLUSIONS: Data collected over 6 seasons indicate a higher risk of sustaining an injury playing summer RL, but the cause may be related to a combination of factors. These may include the ground or weather conditions associated with summer rugby, player characteristics or changes in the game itself and future research needs to investigate these further. 相似文献
3.
P. Boissonnat M. de Lorgeril V. Perroux P. Salen A. M. Batt J. C. Barthelemy R. Brouard E. Serres J. Delaye 《European journal of clinical pharmacology》1997,53(1):39-45
Objectives: Previous uncontrolled studies have suggested an interaction between ticlopidine, a major antiplatelet agent, and cyclosporin
in heart- and kidney-transplant recipients. The aims of this study were to examine in a randomised, double-blind fashion,
the possible interaction between cyclosporin A and ticlopidine (250 mg per day) and the tolerability of this combination in
heart-transplant recipients.
Methods: Twenty heart-transplant recipients were randomised into either a treated or a placebo group. Blood samples were drawn for
time-course evaluation of cyclosporin blood levels over a period of 12 h, following the morning intake of cyclosporin and,
for platelet aggregation studies, before and after 14 days of ticlopidine administration. Twenty four-hour urine samples were
collected for 6-β-hydroxycortisol measurements, before and after 14 days of ticlopidine.
Results: Although given at half the recommended daily dosage, ticlopidine significantly reduced platelet aggregation. Pharmacokinetic
parameters indicate that the bioavailability of cyclosporin A was not significantly modified by ticlopidine. However, one
patient in the ticlopidine group was withdrawn because of a major fall in cyclosporin blood level within 3 days of treatment.
Urinary excretion of 6-β-hydroxycortisol was augmented after treatment in the ticlopidine group compared with the placebo
group, suggesting that induction of drug metabolism might have occurred. Data also show quite a large intra-individual variability
in cyclosporin bioavailability in the placebo group, suggesting that poor absorption of the drug formulation and/or poor compliance
might have contributed to the decreased cyclosporin blood levels in the patient withdrawn from this study and in previous
uncontrolled studies.
Conclusion: Cyclosporin bioavailability was not clearly modified by a half dosage of ticlopidine in this study. We, however, recommend
closely monitoring cyclosporin blood levels when prescribing ticlopidine. Further studies will be needed with new formulations
of cyclosporin or when using the full dosage of ticlopidine.
Received: 20 July 1996 / Accepted in revised form: 12 February 1997 相似文献
4.
5.
6.
7.
8.
9.
10.